drugset / Trial / NCT00182533

Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders

NCT00182533

Phase 4 Terminated 170 enrolled Hamilton Health Sciences Corporation Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.

Timeline

Start
2002-07
Primary completion
2018-01
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sertraline Small molecule